期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 13, 页码 6727-6740出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b02150
关键词
-
资金
- Aventis Foundation
- Else-Kroener-Fresenius-Foundation
- German cancer network DKTK
- SGC, a registered charity
- AbbVie
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for Innovation
- Genome Canada
- Innovative Medicines Initiative (EU/EFPIA)
- Janssen
- Merck KGaA Darmstadt Germany
- MSD
- Novartis Pharma AG
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Sao Paulo Research Foundation-FAPESP
- Takeda
- Wellcome
- European Union's Horizon 2020 research and innovation program [730872]
Thyroid hormones (THs) operate numerous physiological processes through modulation of the nuclear thyroid hormone receptors and several other proteins. We report direct activation of the nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) and retinoid X receptor (RXR) by classical and nonclassical THs as another molecular activity of THs. The T4 metabolite TETRAC was the most active TH on PPAR gamma with nanomolar potency and binding affinity. We demonstrate that TETRAC promotes PPAR gamma/RXR signaling in cell-free, cellular, and in vivo settings. Simultaneous activation of the heterodimer partners PPAR gamma and RXR resulted in high dimer activation efficacy. Compared to fatty acids as known natural ligands of PPAR gamma and RXR, TETRAC differs markedly in its molecular structure and the PPAR gamma-TETRAC complex revealed a distinctive binding mode of the TH. Our observations suggest a potential connection of TH and PPAR signaling through overlapping ligand recognition and may hold implications for TH and PPAR pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据